Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile

Fox K et al. Lancet 2008;372:807-16

Baseline characteristics


Baseline characteristics of the subgroup with heart rate of 70 bpm or greater


Mean heart rate during the study (A) in the total study population and (B) in the subgroup

with heart rate of 70 bpm or greater


Incidence of serious adverse events during the study by system organ class


Primary and secondary endpoints


Kaplan–Meier time-to-event plot, by treatment group for composite primary endpoint in the total study population


Effect of treatment on composite primary endpoint in prespecified subgroups


Kaplan–Meier time-to-event plot, by treatment group in the prespecified subgroup with heart rate of

70 bpm or greater for composite primary endpoint


Kaplan–Meier time-to-event plots, by

treatment group in the prespecifi ed subgroup

with heart rateof 70 bpm or greater,

for the secondary endpoints of (A)

admission to hospital for new-onset or

worsening heart failure and (B) cardiovascular

death or admission to hospital for new-onset or worsening

heart failure


Kaplan–Meier time-to-event plots, by

treatment group in the prespecifi ed subgroup

with heart rateof 70 bpm or greater

for the secondary endpoints of (A)

admission to hospital for acute myocardial

infarction endpoint and (B) admission to hospital for acute

myocardial infarction or unstable angina


Kaplan–Meier time-to-event plot, by treatment group in the prespecified subgroup with heart rate of 70 bpm or greater

for secondary endpoint of coronary revascularisation


Trial profile Fox K et al. Lancet 2008;372:807-16.

Documents

greater fox

secondary endpoints

worsening heart failure

composite primary endpoint

mean heart rate

treatment group

prespecified subgroups

baseline characteristics